Loading
A phase 2 trial of Acalabrutinib, Rituximab in diffuse large b-cell lymphoma, run by AstraZeneca, now recruiting.
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL is a phase 2 interventional study registered as NCT05952024 by AstraZeneca, with 80 participants planned, started 2024-07-16 and due to reach its primary completion in 2029-04-22. Interventions recorded: Acalabrutinib, Rituximab. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Shares Acalabrutinib, Rituximab, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Rituximab, AstraZeneca, Monoclonal antibodies.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/